Skip to main content

Table 2 Summary of derived plasma GSK2239633 pharmacokinetic parameters in the microdose intravenous study

From: Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised study

  [14C]-GSK2239633 (n = 6) Total plasma drug-related radioactivity (n = 6)
Parameters Geometric mean (95% CI) Geometric mean (95% CI)*
Cmax (ng/mL) 7.451 (6.114, 9.079) 8.380 (7.503, 9.359)
AUC0–48 (ng.hour/mL) 4.420 (3.515, 5.556) 8.840 (7.538, 10.368)
AUC0–∞ (ng.hour/mL) 4.577 (3.606, 5.810) 11.418 (9.004, 14.480)
t½ (hour)1 13.5 [8.0–21.2] 31.6 [25.1–43.0]
CL (L/hour) 21.9 (17.2, 27.7) 8.8 (6.9, 11.1)
Vss (L) 119.0 (78.4, 182.0) 249.0 (200.0, 309.0)
Vd (L) 424.0 (275.0, 654.0) 399.0 (322.0, 494.0)
  1. * Concentrations are in ng GSK2239633 equiv/mL and ng GSK2239633 equiv.hour/mL for Cmax and AUC, respectively.
  2. 1 Median [range].
  3. CI: confidence interval; Cmax: maximum observed concentration; AUC0–48: area under the concentration-time curve from time 0 to 48 hours post-dose; AUC0–∞: area under the concentration-time curve from time 0 extrapolated to infinity; t½: half-life; CL: apparent clearance; Vss: volume of distribution at steady state; Vd: volume of distribution during terminal elimination phase.